Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: Developer, manufacturer, and seller of life science technologies, products, and services for research, pharmaceutical discovery, and bioproduction. Operations span the U.S., Europe, and China.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Revenues | $23,097 | $28,759 | $47,609 | $58,734 |
| Gross Profit | $13,218 | $16,673 | $27,990 | $35,019 |
| Gross Margin | 57.2% | 58.0% | 58.8% | 59.6% |
| Operating Income (Loss) | $(2,069) | $796 | $(4,348) | $2,545 |
| Net Loss | $(2,927) | $(980) | $(7,621) | $(358) |
| Diluted EPS | $(0.07) | $(0.02) | $(0.18) | $(0.01) |
| Cash from Operations (YTD) | $557 | $5,364 | ||
| Cash & Equivalents (End of Period) | ||||
| Total Debt (Gross) | $36.1 million (as of June 30, 2024) |
Material Changes vs. Prior Period
- Revenue Decline: Q2 2024 revenue decreased 19.7% year-over-year (YoY) to $23.1 million. YTD revenue decreased 18.9% to $47.6 million. Management attributes this to softening worldwide demand, specifically in China and the Asia-Pacific region, and reduced spending by biotechnology and pharmaceutical customers.
- Operating Loss: The company reported an operating loss of $2.1 million in Q2 2024, compared to operating income of $0.8 million in Q2 2023. This shift was driven by lower revenues and under-absorption of fixed manufacturing overhead.
- Restructuring Costs: The company incurred $0.4 million in restructuring expenses in Q2 2024, primarily for severance related to headcount reductions in Europe and North America.
- Equity Securities: The company sold all remaining shares of Harvard Apparatus Regenerative Technology, Inc. (HRGN) in Q2 2024, recording a loss of $0.3 million for the quarter ($1.6 million YTD).
- Employee Retention Credit (ERC): The company received $3.2 million in ERC refunds during the first half of 2024, which positively impacted cash flow from operations but included $0.5 million in associated fees.
Guidance, Outlook, and Risks
- Liquidity and Debt: As of June 30, 2024, the company had $4.0 million in cash and $5.4 million in available borrowing capacity under its revolving credit facility. Total debt was $36.1 million. Management expects current resources to be sufficient for at least the next 12 months.
- Credit Agreement Amendment: On August 6, 2024, the company amended its Credit Agreement to modify financial covenants (net leverage and fixed charge coverage ratios) through December 31, 2024. This amendment ensures compliance but includes a 50bps interest rate margin increase if the net leverage ratio exceeds 3.0 until year-end financials are delivered.
- Risk Factors: Key risks include global economic uncertainty, inflation, higher interest rates, currency fluctuations, and continued softening in international markets (particularly China). The company also faces risks related to government funding delays for customers.
- Unclaimed Property: The company recorded a $0.3 million expense related to unclaimed property audits in the first half of 2024.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the impact of the August 2024 Credit Agreement amendment on future borrowing costs and leverage ratio requirements.
- Revenue Recovery: Monitor trends in the China and Asia-Pacific regions and spending levels of biotech/pharma customers to assess revenue stabilization.
- Cash Burn vs. Generation: Review the sustainability of operating cash flows given the significant decline in net income and the one-time nature of the ERC refunds.
- Restructuring Progress: Track the realization of cost savings from the headcount reductions and restructuring activities initiated in Q2 2024.
- Inventory Levels: Assess inventory turnover given the increase in raw materials and finished goods relative to the revenue decline.